OBJECTIVE: Although fibromyalgia (FM) is traditionally a non-inflammatory condition, emerging data also suggest that FM has an immunologic component. Previous studies have reported that peripheral blood concentrations of two chemokines (i.e., interleukin-8 [IL-8] and monocyte chemotactic protein-1 [MCP-1]) were elevated in FM patients compared with normal controls. We sought to determine the longitudinal relationships of changes in the levels (picogram/mL) of IL-8 and MCP-1 with changes in the severity of FM-related pain. DESIGN: Secondary data analysis of a cohort of 16 FM subjects who provided blood samples at two time points: week 1 and week 12. Setting. Urban rheumatology clinic practices. PATIENTS: Individuals who met the American College of Rheumatology 1990 criteria for FM. OUTCOME MEASURES: Changes from week 1 to week 12 of the following variables: Brief Pain Inventory (BPI) pain severity and plasma concentrations of IL-8 and MCP-1. RESULTS: Change in BPI pain severity was significantly associated with changes in IL-8 and MCP-1 plasma concentrations. Specifically, for each unit increase in the change of BPI pain severity, IL-8 increased by 2.5 pg/mL (P = 0.03) and MCP-1 increased by 9.4 pg/mL (P = 0.006). None of the covariates (i.e., body mass index, medications, severity of depression, and overall FM burden) were significantly associated with either chemokines. CONCLUSION: Although preliminary, our findings raise the hypothesis that IL-8 and MCP-1 may be involved in the pathogenesis of FM. If replicated in a larger study, IL-8 and MCP-1 may assist in determining prognosis and in monitoring of treatment response. Wiley Periodicals, Inc.
OBJECTIVE: Although fibromyalgia (FM) is traditionally a non-inflammatory condition, emerging data also suggest that FM has an immunologic component. Previous studies have reported that peripheral blood concentrations of two chemokines (i.e., interleukin-8 [IL-8] and monocyte chemotactic protein-1 [MCP-1]) were elevated in FM patients compared with normal controls. We sought to determine the longitudinal relationships of changes in the levels (picogram/mL) of IL-8 and MCP-1 with changes in the severity of FM-related pain. DESIGN: Secondary data analysis of a cohort of 16 FM subjects who provided blood samples at two time points: week 1 and week 12. Setting. Urban rheumatology clinic practices. PATIENTS: Individuals who met the American College of Rheumatology 1990 criteria for FM. OUTCOME MEASURES: Changes from week 1 to week 12 of the following variables: Brief Pain Inventory (BPI) pain severity and plasma concentrations of IL-8 and MCP-1. RESULTS: Change in BPI pain severity was significantly associated with changes in IL-8 and MCP-1 plasma concentrations. Specifically, for each unit increase in the change of BPI pain severity, IL-8 increased by 2.5 pg/mL (P = 0.03) and MCP-1 increased by 9.4 pg/mL (P = 0.006). None of the covariates (i.e., body mass index, medications, severity of depression, and overall FM burden) were significantly associated with either chemokines. CONCLUSION: Although preliminary, our findings raise the hypothesis that IL-8 and MCP-1 may be involved in the pathogenesis of FM. If replicated in a larger study, IL-8 and MCP-1 may assist in determining prognosis and in monitoring of treatment response. Wiley Periodicals, Inc.
Authors: Britta Torgrimson-Ojerio; Rebecca L Ross; Nathan F Dieckmann; Stephanie Avery; Robert M Bennett; Kim D Jones; Anthony J Guarino; Lisa J Wood Journal: J Neuroimmunol Date: 2014-10-18 Impact factor: 3.478
Authors: Katie S Payne; Karen Schilli; Katlyn Meier; Ryan K Rader; Jonathan A Dyer; James W Mold; Jonathan A Green; William V Stoecker Journal: JAMA Dermatol Date: 2014-11 Impact factor: 10.282
Authors: John A Sturgeon; Beth D Darnall; Heather L Zwickey; Lisa J Wood; Douglas A Hanes; David T Zava; Sean C Mackey Journal: J Pain Res Date: 2014-12-04 Impact factor: 3.133